<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130738</url>
  </required_header>
  <id_info>
    <org_study_id>HD-MCZ-PHII-DRF062016</org_study_id>
    <nct_id>NCT03130738</nct_id>
  </id_info>
  <brief_title>Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis</brief_title>
  <official_title>Dose-Ranging Study of the Efficacy and Safety of Miconazole Oil Used for 7 or 14 Days Compared With Vehicle in the Treatment of Otomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hill Dermaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QST Consultations, Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hill Dermaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of active treatment
      (miconazole oil) for 7 versus 14 days, and to compare 14 days of active treatment (miconazole
      oil) to inactive treatment (placebo) over a 14-day treatment duration, in subjects with
      fungal infection (otomycosis) of the external ear.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Miconazole, an imidazole antifungal agent, is commonly used for different types of fungal
      skin infections, such as Candida, ringworm, jock itch, athlete's foot, nail fungus, vaginal
      yeast infections, and oropharyngeal candidiasis. The 2% formulation of miconazole is commonly
      used for dermatophytic infections. The mechanisms of action of miconazole against fungi in
      general appear to be applicable to fungi associated with otomycosis, in that miconazole has
      been demonstrated to have activity in vitro against some clinical isolates of fungi
      associated with human otomycosis in the US.

      Miconazole targets the cytochrome P450-dependent enzyme 14-α-sterol demethylase, an enzyme
      that is also involved in mammalian cholesterol synthesis, resulting in inhibition of
      ergosterol biosynthesis in the cell membrane of the fungal organism. Because ergosterol is an
      important component of the cell membrane, inhibition of its synthesis inhibits fungal cell
      growth.

      In addition to its activity toward the enzyme 14-α-sterol demethylase, miconazole also leads
      to increased reactive oxygen species in fungal organisms, which appears to result in
      fungicidal activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Actual">August 6, 2019</completion_date>
  <primary_completion_date type="Actual">August 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Subjects, investigators, and study staff will not be masked as to the treatment duration assigned to each subject (7 versus 14 days). For subjects receiving the 14-day treatment with study drug, the contents of the study drug (active versus placebo) will be masked to the subject, investigator, and study staff.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>At Test of Cure visit (Day 15 for 7 Day Active and Day 22 for 14 Day Active and 14 Day Vehicle)</time_frame>
    <description>Percentage of subjects in MITT population, at the &quot;Test of Cure&quot; visit with &quot;Therapeutic cure&quot;, defined as a negative fungal culture plus &quot;clinical cure&quot; defined as the absence of all otomycosis signs and symptoms for pruritus, debris, fungal elements, and pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoints</measure>
    <time_frame>At Test of Cure visit (Day 15 for 7 Day Active and Day 22 for 14 Day Active and 14 Day Vehicle)</time_frame>
    <description>Percentage of subjects in MITT population with clinical cure at the Test of Cure Visit
Percentage of subjects in MITT population with a negative fungal culture at the Test of Cure Visit
Percentage of subjects in MITT population with a negative fungal culture at the Test of Cure visit as well as individual sign or symptom score of 0 or 1 on each of the scales for pruritus and debris and a score of 0 on each of the scales for fungal elements and pain (Secondary therapeutic cure).
Percentage of subjects in MITT population with individual signs or symptoms with a score of 0 or 1 on each of the scales for pruritus and debris and a score of 0 on each of the scales for fungal elements and pain (Secondary clinical cure).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Otomycosis</condition>
  <arm_group>
    <arm_group_label>7-Day Miconazole Oil (Miconazole 2%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14-Day Miconazole Oil (Miconazole 2%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14-Day Placebo - Oil Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-Day Miconazole Oil (Miconazole 2%)</intervention_name>
    <description>7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
    <arm_group_label>7-Day Miconazole Oil (Miconazole 2%)</arm_group_label>
    <other_name>Miconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14-Day Miconazole Oil (Miconazole 2%)</intervention_name>
    <description>14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
    <arm_group_label>14-Day Miconazole Oil (Miconazole 2%)</arm_group_label>
    <other_name>Miconazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14-Day Placebo - Oil Vehicle</intervention_name>
    <description>14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient</description>
    <arm_group_label>14-Day Placebo - Oil Vehicle</arm_group_label>
    <other_name>(Miconazole) Placebo Oil Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Uncomplicated otomycosis of the external ear only, age more than 2 year

        Exclusion Criteria:

          -  Pregnancy

          -  Other dermatoses or conditions of the ear that may interfere with the evaluation of
             otomycosis, including concomitant otic infections (including bacterial infection) that
             require antimicrobial treatment, disease that has spread beyond the external ear(s),
             or pre-existing skin atrophy of the affected ear(s)

          -  Tympanostomy tube or perforated tympanic membrane in the ear(s) that will be treated

          -  Previous surgery affecting the ear(s) that will be treated, except for prior
             tympanostomy tube(s) that had been removed and had completely healed

          -  Previous use of medicated treatments for otomycosis or participation in another
             investigational study within 28 days of study entry

          -  Previous use of any systemic antifungal therapy, warfarin, and immunosuppressive or
             immune-stimulating drugs within 28 days of study entry, or systemic steroids within 3
             months of study entry

          -  Recurrent otomycosis that had been unresponsive to previous antifungal treatment

          -  Known hypersensitivity to any of the components in the test formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosario G Ramirez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hill Dermaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jack Wazen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Silverstein Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Quyen T Nguyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth Hodge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced ENT and Allergy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth S Maxwell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Ear, Nose and Throat Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo Linda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head and Neck Surgery Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Head and Neck Surgery Specialist</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ear Nose and Throat Associates of Southe Florida</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silverstein Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced ENT and Allergy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont ENT Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <results_first_submitted>April 8, 2020</results_first_submitted>
  <results_first_submitted_qc>April 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 22, 2020</results_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Otomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miconazole</mesh_term>
    <mesh_term>Clotrimazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 17, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03130738/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT03130738/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>7-Day Miconazole Oil (Miconazole 2%)</title>
          <description>7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
7-Day Miconazole Oil (Miconazole 2%): 7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
        </group>
        <group group_id="P2">
          <title>14-Day Miconazole Oil (Miconazole 2%)</title>
          <description>14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
14-Day Miconazole Oil (Miconazole 2%): 14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
        </group>
        <group group_id="P3">
          <title>14-Day Placebo - Oil Vehicle</title>
          <description>14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
14-Day Placebo - Oil Vehicle: 14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline participants from ITT population which consisted of subjects entered and randomized, by randomized group. ITT population includes MITT population.</population>
      <group_list>
        <group group_id="B1">
          <title>7-Day Miconazole Oil (Miconazole 2%)</title>
          <description>7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
7-Day Miconazole Oil (Miconazole 2%): 7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
        </group>
        <group group_id="B2">
          <title>14-Day Miconazole Oil (Miconazole 2%)</title>
          <description>14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
14-Day Miconazole Oil (Miconazole 2%): 14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
        </group>
        <group group_id="B3">
          <title>14-Day Placebo - Oil Vehicle</title>
          <description>14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
14-Day Placebo - Oil Vehicle: 14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" lower_limit="11" upper_limit="84"/>
                    <measurement group_id="B2" value="66.0" lower_limit="8" upper_limit="86"/>
                    <measurement group_id="B3" value="62.5" lower_limit="20" upper_limit="85"/>
                    <measurement group_id="B4" value="64" lower_limit="11" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy Endpoint</title>
        <description>Percentage of subjects in MITT population, at the &quot;Test of Cure&quot; visit with &quot;Therapeutic cure&quot;, defined as a negative fungal culture plus &quot;clinical cure&quot; defined as the absence of all otomycosis signs and symptoms for pruritus, debris, fungal elements, and pain.</description>
        <time_frame>At Test of Cure visit (Day 15 for 7 Day Active and Day 22 for 14 Day Active and 14 Day Vehicle)</time_frame>
        <population>Actual number of participants analyzed under Primary efficacy endpoint are MITT population, defined as subjects who had a clinical diagnosis of otomycosis confirmed by positive fungal culture.</population>
        <group_list>
          <group group_id="O1">
            <title>7-Day Miconazole Oil (Miconazole 2%)</title>
            <description>7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
7-Day Miconazole Oil (Miconazole 2%): 7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
          </group>
          <group group_id="O2">
            <title>14-Day Miconazole Oil (Miconazole 2%)</title>
            <description>14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
14-Day Miconazole Oil (Miconazole 2%): 14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
          </group>
          <group group_id="O3">
            <title>14-Day Placebo - Oil Vehicle</title>
            <description>14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
14-Day Placebo - Oil Vehicle: 14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy Endpoint</title>
          <description>Percentage of subjects in MITT population, at the &quot;Test of Cure&quot; visit with &quot;Therapeutic cure&quot;, defined as a negative fungal culture plus &quot;clinical cure&quot; defined as the absence of all otomycosis signs and symptoms for pruritus, debris, fungal elements, and pain.</description>
          <population>Actual number of participants analyzed under Primary efficacy endpoint are MITT population, defined as subjects who had a clinical diagnosis of otomycosis confirmed by positive fungal culture.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy Endpoints</title>
        <description>Percentage of subjects in MITT population with clinical cure at the Test of Cure Visit
Percentage of subjects in MITT population with a negative fungal culture at the Test of Cure Visit
Percentage of subjects in MITT population with a negative fungal culture at the Test of Cure visit as well as individual sign or symptom score of 0 or 1 on each of the scales for pruritus and debris and a score of 0 on each of the scales for fungal elements and pain (Secondary therapeutic cure).
Percentage of subjects in MITT population with individual signs or symptoms with a score of 0 or 1 on each of the scales for pruritus and debris and a score of 0 on each of the scales for fungal elements and pain (Secondary clinical cure).</description>
        <time_frame>At Test of Cure visit (Day 15 for 7 Day Active and Day 22 for 14 Day Active and 14 Day Vehicle)</time_frame>
        <population>Percentage of subjects in the MITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>7-Day Miconazole Oil (Miconazole 2%)</title>
            <description>7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
7-Day Miconazole Oil (Miconazole 2%): 7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
          </group>
          <group group_id="O2">
            <title>14-Day Miconazole Oil (Miconazole 2%)</title>
            <description>14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
14-Day Miconazole Oil (Miconazole 2%): 14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
          </group>
          <group group_id="O3">
            <title>14-Day Placebo - Oil Vehicle</title>
            <description>14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
14-Day Placebo - Oil Vehicle: 14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy Endpoints</title>
          <description>Percentage of subjects in MITT population with clinical cure at the Test of Cure Visit
Percentage of subjects in MITT population with a negative fungal culture at the Test of Cure Visit
Percentage of subjects in MITT population with a negative fungal culture at the Test of Cure visit as well as individual sign or symptom score of 0 or 1 on each of the scales for pruritus and debris and a score of 0 on each of the scales for fungal elements and pain (Secondary therapeutic cure).
Percentage of subjects in MITT population with individual signs or symptoms with a score of 0 or 1 on each of the scales for pruritus and debris and a score of 0 on each of the scales for fungal elements and pain (Secondary clinical cure).</description>
          <population>Percentage of subjects in the MITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Fungal Culture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Therapeutic Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Clinical Cure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study duration for each subject was up to 30 days (up to 14 days of treatment, and 8 days of follow-up, including the visit window of up to 8 additional days after the scheduled day to complete the final visit), starting from entry and randomization in the study. Start at Screening Visit and ends at final visit which is the Test of cure visit.</time_frame>
      <desc>AEs were recorded and classified using MedDRA terminology. All treatment-emergent adverse events (TEAEs), defined as any AE with onset on or after date of first study drug application, summarized by drug group, number of subjects reporting TEAE, system organ class, preferred term, severity, relationship to study drug, and seriousness. Each subject counted once within a system organ class or preferred term using event with the highest severity and greatest relationship within each classification.</desc>
      <group_list>
        <group group_id="E1">
          <title>7-Day Miconazole Oil (Miconazole 2%)</title>
          <description>7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
7-Day Miconazole Oil (Miconazole 2%): 7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
        </group>
        <group group_id="E2">
          <title>14-Day Miconazole Oil (Miconazole 2%)</title>
          <description>14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
14-Day Miconazole Oil (Miconazole 2%): 14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)</description>
        </group>
        <group group_id="E3">
          <title>14-Day Placebo - Oil Vehicle</title>
          <description>14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
14-Day Placebo - Oil Vehicle: 14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA (20.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain. Tympanic membrane perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>discharge. discomfort. erosion. pain. pruritus. site pain</sub_title>
                <description>administration site conditions</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>site infection. ear fugal infection. myringitis.bacterial otitis externa. otitis media. skin infecti</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthritis. rheumatoid arthritis.</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>rheumatoid lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Proprietary Information will need prior written consent of the sponsor. PI will hold in confidence and not disclose any Proprietary Information unless disclosure has its prior written consent from sponsor, or that the information is disclosed to personnel who need to know. Sponsor will not prohibit PI to comply with applicable laws and regulations, provided PI gives prior written notice to Sponsor. Disclosure allowed if legally required and accorded confidential treatment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rosario G Ramirez, MD</name_or_title>
      <organization>Hill Dermaceuticals, Inc.</organization>
      <phone>407-323-1887</phone>
      <email>nini.ramirez@hillderm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

